A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia
Principal Investigator (PI)
Clinical Trials.gov ID
Key Eligibility
Protocol #
SPONSOR
